MX2020002436A - Antagonistas del receptor de vasopresina y productos y metodos relacionados a los mismos. - Google Patents

Antagonistas del receptor de vasopresina y productos y metodos relacionados a los mismos.

Info

Publication number
MX2020002436A
MX2020002436A MX2020002436A MX2020002436A MX2020002436A MX 2020002436 A MX2020002436 A MX 2020002436A MX 2020002436 A MX2020002436 A MX 2020002436A MX 2020002436 A MX2020002436 A MX 2020002436A MX 2020002436 A MX2020002436 A MX 2020002436A
Authority
MX
Mexico
Prior art keywords
sup
products
receptor antagonists
methods related
vasopressin receptor
Prior art date
Application number
MX2020002436A
Other languages
English (en)
Inventor
Mark Chambers
Chris Knight
Mariangela Urbano
Robert M Jones
Gary Brandt
David Hardick
Jason Tierney
Chris Lock
Original Assignee
Blackthorn Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blackthorn Therapeutics Inc filed Critical Blackthorn Therapeutics Inc
Publication of MX2020002436A publication Critical patent/MX2020002436A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporcionan compuestos que antagonizan los receptores de vasopresina, particularmente los productos del receptor V1a que contienen dichos compuestos, así como los métodos de su uso y síntesis. Tales compuestos tienen la estructura de la Fórmula (I), o un isómero, racemato, hidrato, solvato, isótopo o sal farmacéuticamente aceptable del mismo: (ver Fórmula) en donde Q1, Q2, Q3, R2a, R2b, R3 y X son como se definen en la presente.
MX2020002436A 2017-09-05 2018-09-05 Antagonistas del receptor de vasopresina y productos y metodos relacionados a los mismos. MX2020002436A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762554452P 2017-09-05 2017-09-05
PCT/US2018/049607 WO2019050988A1 (en) 2017-09-05 2018-09-05 ANTAGONISTS OF THE VASOPRESSIN RECEPTOR, PRODUCTS AND RELATED METHODS

Publications (1)

Publication Number Publication Date
MX2020002436A true MX2020002436A (es) 2020-07-13

Family

ID=63708454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002436A MX2020002436A (es) 2017-09-05 2018-09-05 Antagonistas del receptor de vasopresina y productos y metodos relacionados a los mismos.

Country Status (13)

Country Link
US (2) US10538530B2 (es)
EP (1) EP3679043B9 (es)
JP (1) JP7368357B2 (es)
KR (1) KR20200051686A (es)
CN (1) CN111212842B (es)
AU (1) AU2018330423B2 (es)
CA (1) CA3072766A1 (es)
ES (1) ES2951874T3 (es)
IL (1) IL272563B2 (es)
MX (1) MX2020002436A (es)
SG (1) SG11202001498QA (es)
WO (1) WO2019050988A1 (es)
ZA (1) ZA202001027B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106810536A (zh) 2015-11-30 2017-06-09 甘李药业股份有限公司 一种蛋白激酶抑制剂及其制备方法和医药用途
AU2021338497A1 (en) 2020-09-03 2023-02-09 F. Hoffmann-La Roche Ag Heterocyclic compounds
WO2022223750A1 (en) * 2021-04-23 2022-10-27 F. Hoffmann-La Roche Ag Heterocyclic compounds
WO2023130050A1 (en) * 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain
WO2023130043A1 (en) * 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Monoacylglycerol lipase inhibitors and use thereof for the treatment of anxiety
WO2024033479A1 (en) * 2022-08-11 2024-02-15 Remynd N.V. (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2025005A (en) * 1930-01-02 1935-12-17 Union Switch & Signal Co Multiple control apparatus
DE3930262A1 (de) * 1989-09-11 1991-03-21 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5091387A (en) * 1990-03-02 1992-02-25 Merck & Co., Inc. Spirocyclic oxytocin antagonists
ES2218191T3 (es) * 1999-07-21 2004-11-16 Astrazeneca Ab Nuevos compuestos.
US20060063791A1 (en) * 2004-09-17 2006-03-23 An-Hu Li (Spirocyclylamido)aminothiophene compounds
MX2008000886A (es) * 2005-07-21 2008-03-18 Hoffmann La Roche Derivados de indol-3-il-carbonil-piperidin-benzoimidazol como antagonistas del receptor v1a.
US7351706B2 (en) * 2006-01-05 2008-04-01 Hoffmann-La Roche Inc. Indol-3-yl-carbonyl-spiro-piperidine derivatives
US7825111B2 (en) * 2006-09-22 2010-11-02 Janssen Pharmaceutica Nv Substituted spiroheterocycles
ATE469900T1 (de) * 2006-12-07 2010-06-15 Hoffmann La Roche Spiropiperidinderivate als antagonisten des via- rezeptors
CN101541797A (zh) * 2006-12-07 2009-09-23 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
US8329904B2 (en) * 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
AU2010299916A1 (en) * 2009-09-24 2012-03-08 Shire-Movetis N.V. [1,4]-benzodiazepines as vasopressin V2 receptor antagonists
EP2956145A4 (en) * 2013-02-18 2016-08-17 Spring Bank Pharmaceuticals Inc DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINATE ADJUVANTIES AND THERAPEUTICS
JP2016513112A (ja) * 2013-02-18 2016-05-12 ザ スクリプス リサーチ インスティテュート 治療的潜在能力を有するバソプレッシン受容体のモジュレーター
US9688678B2 (en) * 2014-05-15 2017-06-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a nitrogen-bound spiro substituent and use thereof for treating vasopressin-related diseases
US9527856B2 (en) * 2014-05-15 2016-12-27 AbbVie Deutschland GmbH & Co. KG Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases
WO2018226769A1 (en) * 2017-06-05 2018-12-13 Blackthorn Therapeutics, Inc. 1-(2-azaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives as v1a receptor antagonists for treating neuropsychological disorders
US20230084719A1 (en) * 2018-12-12 2023-03-16 Blackthorn Therapeutics, Inc. 1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders

Also Published As

Publication number Publication date
IL272563B (en) 2022-10-01
US20190169202A1 (en) 2019-06-06
IL272563B2 (en) 2023-02-01
EP3679043B1 (en) 2023-05-31
IL272563A (en) 2020-03-31
ZA202001027B (en) 2023-10-25
KR20200051686A (ko) 2020-05-13
ES2951874T3 (es) 2023-10-25
CA3072766A1 (en) 2019-03-14
AU2018330423A1 (en) 2020-03-05
JP2020532592A (ja) 2020-11-12
JP7368357B2 (ja) 2023-10-24
CN111212842A (zh) 2020-05-29
EP3679043B9 (en) 2023-09-27
US20210317126A1 (en) 2021-10-14
CN111212842B (zh) 2022-10-25
SG11202001498QA (en) 2020-03-30
WO2019050988A1 (en) 2019-03-14
AU2018330423B2 (en) 2023-04-06
NZ762031A (en) 2024-04-26
EP3679043A1 (en) 2020-07-15
US10538530B2 (en) 2020-01-21

Similar Documents

Publication Publication Date Title
MX2020002436A (es) Antagonistas del receptor de vasopresina y productos y metodos relacionados a los mismos.
MX2019010980A (es) Antagonistas del receptor opioide kappa y productos y metodos relacionados al mismo.
NZ766284A (en) Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
ZA202007688B (en) Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods, and uses thereof
NZ747259A (en) Soluble c5ar antagonists
PH12020550028A1 (en) Compounds, compositions and methods
MX2020005323A (es) Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa).
WO2017019804A3 (en) Compounds and methods for kinase modulation, and indications therefor
MX2021011647A (es) Moduladores del receptor x4 de proteina g relacionado con mas y productos y metodos relacionados.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
MX2015011913A (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
MX2022006470A (es) Tiromimeticos novedosos.
MX2020008498A (es) Derivados de sobetirome.
MX2020002430A (es) Compuestos inhibidores del receptor 1 del acido lisofosfatidico (lpar1).
CY1120680T1 (el) Ανταγωνιστες η3 που περιεχουν συνταξη πυρηνα φαινοξυπιπεριδινης
MX2021004474A (es) Compuestos que contienen deuterio.
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
MY176921A (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
JOP20200030A1 (ar) مركب خماسي الحلقة
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
CR20200619A (es) Compuestos de cianotriazol y usos de los mismos